HOCM, Hypertrophic Obstructive Cardiomyopathy
Conditions
Keywords
Cryo ablation, Cardiomyopathy
Brief summary
The purpose of the study is to perform endocardial catheter CRyo-Ablation to relieve the LVOT obstruction in patients with Hypertrophic Obstructive Cardiomyopathy. The investigators hypothesize that the investigators will be able to reduce \> 50% of the initial LVOT gradient. This will be considered as a successful procedure.
Interventions
PROCEDURECRyo-Ablation to Treat HOCM.
CRyo-Ablation to Treat Patients With HOCM.
Sponsors
Medtronic
Shaare Zedek Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The patient must be ≥18 years of age 2. The patient has left ventricular outflow tract obstruction with hypertrophic obstructive cardiomyopathy 3. The patient is on optimal medication 4. The patient is not eligible for/failed/refused alcohol ablation 5. The patient is not eligible for/failed/refused myectomy 6. The patient is willing to participate in the study and has signed informed consent 7. The patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved be the appropriate medical ethics committee.
Exclusion criteria
1. Pregnant or nursing patients Female patients of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test 2. Patient has history of or known impaired renal function (Serum creatinine \>2.0 mg/dL or 177 µmol/l) or on dialysis 3. Patient has a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated 4. Patient has a known hypersensivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel and/or contrast sensitivity/allergy that cannot be adequately pre-medicated 5. Patient has other medical illness not related to the hypertrophic cardiomyopathy (e.g., cancer, known malignancy, or cognitive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with limited life expectancy (i.e., less than 1 year) 6. Subject is enrolled or intended to participate in any concurrent drug and/or device study, which would confound the results of this trial as determined by the investigator, during the course of this clinical study 7. Subjects meets the
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute and long term reduction of initial LVOT gradient | Post procedure and up to 12 months follow up |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients with procedure related complications. | During the procedure untill discharge. |
Outcome results
None listed